SG193489A1 - Methods and compositions for predicting response to eribulin - Google Patents
Methods and compositions for predicting response to eribulin Download PDFInfo
- Publication number
- SG193489A1 SG193489A1 SG2013069646A SG2013069646A SG193489A1 SG 193489 A1 SG193489 A1 SG 193489A1 SG 2013069646 A SG2013069646 A SG 2013069646A SG 2013069646 A SG2013069646 A SG 2013069646A SG 193489 A1 SG193489 A1 SG 193489A1
- Authority
- SG
- Singapore
- Prior art keywords
- expression
- biomarker
- eribulin
- subject
- level
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454426P | 2011-03-18 | 2011-03-18 | |
| PCT/US2012/029479 WO2012129100A1 (en) | 2011-03-18 | 2012-03-16 | Methods and compositions for predicting response to eribulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG193489A1 true SG193489A1 (en) | 2013-10-30 |
Family
ID=45879070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013069646A SG193489A1 (en) | 2011-03-18 | 2012-03-16 | Methods and compositions for predicting response to eribulin |
| SG10201602147YA SG10201602147YA (en) | 2011-03-18 | 2012-03-16 | Methods And Compositions For Predicting Response To Eribulin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201602147YA SG10201602147YA (en) | 2011-03-18 | 2012-03-16 | Methods And Compositions For Predicting Response To Eribulin |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637795B2 (https=) |
| EP (1) | EP2686441B1 (https=) |
| JP (3) | JP2014509515A (https=) |
| CN (1) | CN103562406B (https=) |
| CA (1) | CA2828959A1 (https=) |
| ES (1) | ES2731653T3 (https=) |
| SG (2) | SG193489A1 (https=) |
| WO (1) | WO2012129100A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102369008B (zh) | 2009-03-30 | 2014-10-29 | 卫材R&D管理有限公司 | 脂质体组合物 |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| BR112015029386B1 (pt) * | 2013-06-26 | 2023-11-14 | Eisai R&D Management Co., Ltd. | Uso de eribulina e lenvatinibe como terapia de combinação e kit |
| US20170100367A1 (en) * | 2014-05-28 | 2017-04-13 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
| WO2015184145A1 (en) * | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| AU2016226157B2 (en) * | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
| US10669545B2 (en) | 2015-05-01 | 2020-06-02 | Japan Science And Technology Agency | Tumor cell malignant transformation suppressor and anti-tumor agent |
| PE20231050A1 (es) | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2020179712A1 (en) * | 2019-03-01 | 2020-09-10 | Eisai R&D Management Co., Ltd. | Methods for predicting tumor response to eribulin |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN113174427B (zh) * | 2021-04-29 | 2023-02-28 | 遵义医科大学 | 基于DNA分子检测ERGIC3 mRNA的方法 |
| CN113512733B (zh) * | 2021-05-13 | 2022-07-26 | 浙江工业大学 | 一种电化学nhk反应合成艾日布林中间体的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
| DE69433811T2 (de) | 1993-01-07 | 2005-06-23 | Sequenom, Inc., San Diego | Dns - sequenzierung durch massenspektronomie |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| JP4454151B2 (ja) | 1998-06-17 | 2010-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 大環状類似体及びそれらの使用並びに調製方法 |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| WO2005032347A2 (en) * | 2003-10-01 | 2005-04-14 | The Ohio State University Research Foundation | Determining the chemosensitivity of cells to cytotoxic agents |
| US20060154312A1 (en) * | 2004-12-09 | 2006-07-13 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using halichondrin B analogs |
| TW201132813A (en) * | 2010-03-03 | 2011-10-01 | Koo Foundation Sun Yat Sen Cancer Ct | Methods for classifying and treating breast cancers |
-
2012
- 2012-03-16 EP EP12710643.3A patent/EP2686441B1/en active Active
- 2012-03-16 CA CA2828959A patent/CA2828959A1/en not_active Abandoned
- 2012-03-16 US US14/001,737 patent/US9637795B2/en not_active Expired - Fee Related
- 2012-03-16 ES ES12710643T patent/ES2731653T3/es active Active
- 2012-03-16 SG SG2013069646A patent/SG193489A1/en unknown
- 2012-03-16 JP JP2013558214A patent/JP2014509515A/ja active Pending
- 2012-03-16 CN CN201280013701.8A patent/CN103562406B/zh not_active Expired - Fee Related
- 2012-03-16 SG SG10201602147YA patent/SG10201602147YA/en unknown
- 2012-03-16 WO PCT/US2012/029479 patent/WO2012129100A1/en not_active Ceased
-
2017
- 2017-03-10 JP JP2017046070A patent/JP6612280B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-01 JP JP2019069638A patent/JP2019150027A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20140235707A1 (en) | 2014-08-21 |
| CN103562406A (zh) | 2014-02-05 |
| ES2731653T3 (es) | 2019-11-18 |
| US9637795B2 (en) | 2017-05-02 |
| JP2019150027A (ja) | 2019-09-12 |
| WO2012129100A1 (en) | 2012-09-27 |
| EP2686441B1 (en) | 2019-05-08 |
| JP2017148049A (ja) | 2017-08-31 |
| JP6612280B2 (ja) | 2019-11-27 |
| CA2828959A1 (en) | 2012-09-27 |
| EP2686441A1 (en) | 2014-01-22 |
| JP2014509515A (ja) | 2014-04-21 |
| SG10201602147YA (en) | 2016-05-30 |
| CN103562406B (zh) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9637795B2 (en) | Methods and compositions for predicting response to eribulin | |
| EP3458604B1 (en) | Method for determining sensitivity to a cdk4/6 inhibitor | |
| CA2844793A1 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
| CA2728674A1 (en) | Signatures and determinants associated with metastasis methods of use thereof | |
| JP5224308B2 (ja) | 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用 | |
| AU2009221778A1 (en) | Molecular diagnosis and classification of malignant melanoma | |
| EP2606349A1 (en) | Cancer diagnostic and cancer therapeutic | |
| KR101801980B1 (ko) | 중추신경계 림프종 진단용 조성물 및 이를 이용한 중추신경계 림프종 진단 키트 | |
| Chen et al. | The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma | |
| WO2017069710A1 (en) | Composition for modulating irak1 | |
| US20150177248A1 (en) | Use of sirt7 as novel cancer therapy target and method for treating cancer using the same | |
| WO2020082037A1 (en) | Methods for treating a subtype of small cell lung cancer | |
| KR102238258B1 (ko) | 간암 진단을 위한 신규 바이오마커 및 이를 이용한 치료 방법 | |
| EP3696545A1 (en) | Method for predicting the resistance of melanoma to a treatment with a braf inhibitor | |
| KR102401005B1 (ko) | 고위험군 자궁내막증의 예방 또는 치료용 조성물 | |
| KR20240136713A (ko) | 유방암의 골전이 예측 또는 진단용 조성물 및 이를 포함하는 키트 | |
| US20250002918A1 (en) | Compositions and methods for treatment of mic60 depleted cancers and metastasis | |
| KR101926841B1 (ko) | Srf-yap 및 yap 시그니쳐를 이용한 줄기세포특성을 보이는 기저양 유방암 및 삼중 음성 유방암 진단 및 치료방법 | |
| US20260015672A1 (en) | Biomarkers in pancreatic cancer | |
| KR102431271B1 (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 | |
| KR20230120908A (ko) | 신경교종의 악성도 진단을 위한 바이오마커 및 이의 용도 | |
| KR20230126529A (ko) | 췌장암 진단을 위한 세포외 소포체 유래 miRNA 유전자 바이오마커 및 이의 용도 | |
| CN121874343A (zh) | Rab26作为骨肉瘤的预后评估标志物和治疗靶点的应用 | |
| Baldovini | “IMMUNOHISTOCHEMICAL CHARACTERIZATION OF A SERIES OF PEDIATRIC MEDULLOBLASTOMAS”-Investigation of JAM molecules expression in pediatric medulloblastoma | |
| KR20230014990A (ko) | 대장암 진단 또는 예후 예측용 바이오마커 |